MaxCyte, Inc. (MXCT)
NASDAQ: MXCT · Real-Time Price · USD
4.020
-0.150 (-3.60%)
Feb 18, 2025, 4:00 PM EST - Market closed
MaxCyte Employees
MaxCyte had 143 employees as of December 31, 2023. The number of employees increased by 18 or 14.40% compared to the previous year.
Employees
143
Change (1Y)
18
Growth (1Y)
14.40%
Revenue / Employee
$318,874
Profits / Employee
-$249,902
Market Cap
437.47M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
MXCT News
- 6 days ago - MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs - GlobeNewsWire
- 11 days ago - MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference - GlobeNewsWire
- 19 days ago - Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT) - Business Wire
- 19 days ago - MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments - GlobeNewsWire
- 5 weeks ago - MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - MaxCyte Announces Retirement of Board Member Art Mandell - GlobeNewsWire
- 2 months ago - MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance - GlobeNewsWire
- 3 months ago - MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics - GlobeNewsWire